Stay updated on Nivolumab Combo in MGMT-Silenced mCRC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in MGMT-Silenced mCRC Clinical Trial page.

Latest updates to the Nivolumab Combo in MGMT-Silenced mCRC Clinical Trial page
- ChecktodayChange DetectedThe page has removed a citation regarding improved survival with ipilimumab in patients with metastatic melanoma, which may affect the credibility of the information presented.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the study on 'NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study', which specifies the inclusion criteria and the study's location. Additionally, the version number has been updated from v2.14.4 to v2.15.0.SummaryDifference38%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to Nivolumab Combo in MGMT-Silenced mCRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in MGMT-Silenced mCRC Clinical Trial page.